0 XP   0   0   0

Merck & Company Inc










Financial Health of Merck




Comparing to competitors in the Drug Manufacturers-General industry




  Industry Rankings  


Richest
#8 / 89

Total Sales
#6 / 89

Making Money
#8 / 89

Working Efficiently
#15 / 89

Merck & Company Inc
Buy, Hold or Sell?

Should you buy, hold or sell Merck?

I guess you are interested in Merck & Company Inc. Buy, hold or sell? I don't know! However, I do recommend doing research before doing anything. I will help you with that.

Let's analyse Merck

Let's start. I'm going to help you getting a better view of Merck & Company Inc. At the end you don't have to ask anyone for trading advice. You can make your own decision, with more confidence, the odds in your favor, backed by data.

  1. Company's Financial Health
    A deep dive into the books. How are the numbers doing? Is Merck & Company Inc even making a profit? Is the company skyrocketing? Or is it sinking like the Titanic. The trend is your friend.
  2. Market Valuation
    Finally, you now have an insight of how Merck & Company Inc is doing in the market. If the company is worth buying. The latest step is to find out how other investors value Merck & Company Inc. The closing price on 2022-11-30 was $107.80 per share. Is the company over- or underpriced?
  3. Key Performance Indicators
    A total overlook on how the company is doing. Based on the (trends in) the key performance indicators.
Merck & Company Inc Daily Candlestick Chart

Summary

Financial Health

Profitability Details
 Compared to previous yearCompared to industry
The company is making a huge profit.
Using its assets, the company is less efficient in making profit.
Using its investors money, the company is less efficient in making profit.
Operating Efficiency Details
 Compared to previous yearCompared to industry
The company is operating very efficient.
The company is less efficient in keeping operating costs low.
Liquidity Details
 Compared to previous yearCompared to industry
The company is just able to pay all its short-term debts.
The company is just not able to pay all its short-term debts with the most liquid assets.
Solvency Details
 Compared to previous yearCompared to industry
The company is able to pay all its debts by selling its assets.
The company is just able to pay all its debts with equity.

1.1. Profitability of Merck & Company Inc.

1.1. Profitability
1.1.1. Net Profit Margin

Measures how much net profit Merck earns for each $1 of revenue.

  • Above 10% is considered healthy but always compare Merck to the Drug Manufacturers-General industry mean.
  • A Net Profit Margin of 21.7% means that $0.22 for each $1 in revenue is generated as profit.

Let's take a look of the Net Profit Margin trends of Merck & Company Inc:

  • The MRQ is 21.7%. The company is making a huge profit. +2
  • The TTM is 25.9%. The company is making a huge profit. +2
Trends
Current periodCompared to+/- 
MRQ21.7%TTM25.9%-4.2%
TTM25.9%YOY14.5%+11.4%
TTM25.9%5Y20.5%+5.4%
5Y20.5%10Y20.5%0.0%
Compared to industry (Drug Manufacturers-General)
PeriodCompanyIndustry (mean)+/- 
MRQ21.7%12.5%+9.2%
TTM25.9%15.3%+10.6%
YOY14.5%12.9%+1.6%
5Y20.5%13.0%+7.5%
10Y20.5%14.8%+5.7%
1.1.2. Return on Assets

Shows how efficient Merck is using its assets to generate profit.

  • Above 5% is considered healthy but always compare Merck to the Drug Manufacturers-General industry mean.
  • 3.0% Return on Assets means that Merck generated $0.03 profit for each $1 in assets.

Let's take a look of the Return on Assets trends of Merck & Company Inc:

  • The MRQ is 3.0%. Using its assets, the company is less efficient in making profit.
  • The TTM is 3.6%. Using its assets, the company is less efficient in making profit.
Trends
Current periodCompared to+/- 
MRQ3.0%TTM3.6%-0.5%
TTM3.6%YOY2.0%+1.6%
TTM3.6%5Y2.8%+0.8%
5Y2.8%10Y2.8%0.0%
Compared to industry (Drug Manufacturers-General)
PeriodCompanyIndustry (mean)+/- 
MRQ3.0%1.8%+1.2%
TTM3.6%2.3%+1.3%
YOY2.0%1.8%+0.2%
5Y2.8%2.0%+0.8%
10Y2.8%2.2%+0.6%
1.1.3. Return on Equity

Shows how efficient Merck is using its investors money to generate profit.

  • Above 15%-20% is considered healthy but always compare Merck to the Drug Manufacturers-General industry mean.
  • 7.5% Return on Equity means Merck generated $0.08 for each $1 the owners (shareholders) invested.

Let's take a look of the Return on Equity trends of Merck & Company Inc:

  • The MRQ is 7.5%. Using its investors money, the company is less efficient in making profit.
  • The TTM is 9.3%. Using its investors money, the company is less efficient in making profit.
Trends
Current periodCompared to+/- 
MRQ7.5%TTM9.3%-1.7%
TTM9.3%YOY5.2%+4.0%
TTM9.3%5Y7.6%+1.7%
5Y7.6%10Y7.6%0.0%
Compared to industry (Drug Manufacturers-General)
PeriodCompanyIndustry (mean)+/- 
MRQ7.5%4.4%+3.1%
TTM9.3%4.8%+4.5%
YOY5.2%4.7%+0.5%
5Y7.6%4.4%+3.2%
10Y7.6%4.6%+3.0%

1.2. Operating Efficiency of Merck & Company Inc.

1.2. Operating Efficiency
1.2.1. Operating Margin

Measures how efficient Merck is operating .

  • Measures how much profit Merck makes for each $1 of sales after paying variable costs (production costs, wages, etc) but before taxes.
  • Above 15% is considered healthy but always compare Merck to the Drug Manufacturers-General industry mean.
  • An Operating Margin of 34.4% means the company generated $0.34  for each $1 in revenue (before taxes).

Let's take a look of the Operating Margin trends of Merck & Company Inc:

  • The MRQ is 34.4%. The company is operating very efficient. +2
  • The TTM is 34.9%. The company is operating very efficient. +2
Trends
Current periodCompared to+/- 
MRQ34.4%TTM34.9%-0.5%
TTM34.9%YOY31.0%+3.9%
TTM34.9%5Y29.3%+5.6%
5Y29.3%10Y29.3%0.0%
Compared to industry (Drug Manufacturers-General)
PeriodCompanyIndustry (mean)+/- 
MRQ34.4%17.1%+17.3%
TTM34.9%18.0%+16.9%
YOY31.0%17.8%+13.2%
5Y29.3%18.1%+11.2%
10Y29.3%18.1%+11.2%
1.2.2. Operating Ratio

Measures how efficient Merck is keeping operating costs low.

  • Below 1 is considered healthy (always compare to Drug Manufacturers-General industry mean).
  • An Operation Ratio of 0.99 means that the operating costs are $0.99 for each $1 in net sales.

Let's take a look of the Operating Ratio trends of Merck & Company Inc:

  • The MRQ is 0.989. The company is less efficient in keeping operating costs low.
  • The TTM is 0.981. The company is less efficient in keeping operating costs low.
Trends
Current periodCompared to+/- 
MRQ0.989TTM0.981+0.007
TTM0.981YOY1.160-0.179
TTM0.9815Y1.065-0.084
5Y1.06510Y1.0650.000
Compared to industry (Drug Manufacturers-General)
PeriodCompanyIndustry (mean)+/- 
MRQ0.9891.085-0.096
TTM0.9811.067-0.086
YOY1.1600.961+0.199
5Y1.0650.964+0.101
10Y1.0650.871+0.194

1.3. Liquidity of Merck & Company Inc.

1.3. Liquidity
1.3.1. Current Ratio

Measures if Merck is able to pay off Short-term Debt.

  • Above 1.5 is considered healthy (always compare to Drug Manufacturers-General industry mean).
  • A Current Ratio of 1.46 means the company has $1.46 in assets for each $1 in short-term debts.

Let's take a look of the Current Ratio trends of Merck & Company Inc:

  • The MRQ is 1.459. The company is just able to pay all its short-term debts.
  • The TTM is 1.378. The company is just able to pay all its short-term debts.
Trends
Current periodCompared to+/- 
MRQ1.459TTM1.378+0.082
TTM1.378YOY1.164+0.214
TTM1.3785Y1.274+0.104
5Y1.27410Y1.2740.000
Compared to industry (Drug Manufacturers-General)
PeriodCompanyIndustry (mean)+/- 
MRQ1.4591.443+0.016
TTM1.3781.398-0.020
YOY1.1641.420-0.256
5Y1.2741.392-0.118
10Y1.2741.381-0.107
1.3.2. Quick Ratio

Measures if Merck is able to pay off Short-term Debt but only using the most liquid assets.

  • Above 1 is considered healthy but always compare Merck to the Drug Manufacturers-General industry mean.
  • A Quick Ratio of 0.46 means the company can pay off $0.46 for each $1 in debt (using most liquid assets).

Let's take a look of the Quick Ratio trends of Merck & Company Inc:

  • The MRQ is 0.465. The company is just not able to pay all its short-term debts with the most liquid assets. -1
  • The TTM is 0.482. The company is just not able to pay all its short-term debts with the most liquid assets. -1
Trends
Current periodCompared to+/- 
MRQ0.465TTM0.482-0.017
TTM0.482YOY0.365+0.117
TTM0.4825Y0.422+0.060
5Y0.42210Y0.4220.000
Compared to industry (Drug Manufacturers-General)
PeriodCompanyIndustry (mean)+/- 
MRQ0.4650.894-0.429
TTM0.4820.822-0.340
YOY0.3650.788-0.423
5Y0.4220.851-0.429
10Y0.4220.830-0.408

1.4. Solvency of Merck & Company Inc.

1.3. Liquidity
1.4.1. Debt to Asset Ratio

Measures how much % of Merck assets are financed with debt.

  • Below 1 (100%) is considered healthy but always compare Merck to Drug Manufacturers-General industry mean.
  • A Debt to Asset Ratio of 0.60 means that Merck assets are financed with 59.6% credit (debt) and the remaining percentage (100% - 59.6%) is financed by its owners/shareholders. 

Let's take a look of the Debt to Asset Ratio trends of Merck & Company Inc:

  • The MRQ is 0.596. The company is able to pay all its debts by selling its assets. +1
  • The TTM is 0.611. The company is able to pay all its debts by selling its assets. +1
Trends
Current periodCompared to+/- 
MRQ0.596TTM0.611-0.016
TTM0.611YOY0.668-0.057
TTM0.6115Y0.644-0.032
5Y0.64410Y0.6440.000
Compared to industry (Drug Manufacturers-General)
PeriodCompanyIndustry (mean)+/- 
MRQ0.5960.487+0.109
TTM0.6110.503+0.108
YOY0.6680.540+0.128
5Y0.6440.525+0.119
10Y0.6440.517+0.127
1.4.2. Debt to Equity Ratio

Measures if Merck is able to pay off its debts by using shareholders equity.

  • Below 2 is considered healthy but always compare Merck to the Drug Manufacturers-General industry mean.
  • A Debt to Equity ratio of 147.5% means that company has $1.47 debt for each $1 in shareholders equity.

Let's take a look of the Debt to Equity Ratio trends of Merck & Company Inc:

  • The MRQ is 1.475. The company is able to pay all its debts with equity. +1
  • The TTM is 1.581. The company is just able to pay all its debts with equity.
Trends
Current periodCompared to+/- 
MRQ1.475TTM1.581-0.106
TTM1.581YOY2.078-0.498
TTM1.5815Y1.857-0.276
5Y1.85710Y1.8570.000
Compared to industry (Drug Manufacturers-General)
PeriodCompanyIndustry (mean)+/- 
MRQ1.4750.952+0.523
TTM1.5811.033+0.548
YOY2.0781.157+0.921
5Y1.8571.140+0.717
10Y1.8571.085+0.772

2. Market Valuation of Merck & Company Inc

2. Earnings Per Share
2.1. Price to Earnings Ratio

Measures how much money you pay for each share for every $1 in earnings Merck generates.

  • Above 15 is considered overpriced but always compare Merck to the Drug Manufacturers-General industry mean.
  • A PE ratio of 64.46 means the investor is paying $64.46 for every $1 in earnings.

Let's take a look of the Price to Earnings Ratio trends of Merck & Company Inc:

  • The EOD is 84.079. Neutral. Compare to industry.
  • The MRQ is 64.463. Neutral. Compare to industry.
  • The TTM is 28.934. Very good. +2
Trends
Current periodCompared to+/- 
EOD84.079MRQ64.463+19.616
MRQ64.463TTM28.934+35.529
TTM28.934YOY10.524+18.410
TTM28.9345Y17.537+11.397
5Y17.53710Y17.5370.000
Compared to industry (Drug Manufacturers-General)
PeriodCompanyIndustry (mean)+/- 
EOD84.07974.978+9.101
MRQ64.46384.344-19.881
TTM28.93477.005-48.071
YOY10.52485.751-75.227
5Y17.53777.578-60.041
10Y17.53767.220-49.683
2.2. Price Earnings to Growth Ratio

Measures the predicted future growth of Merck.

  • Lower is better.
  • A PEG ratio of 1 means the market price of the stock and the expected future earnings are on par.

Let's take a look of the Price Earnings to Growth Ratio trends of Merck & Company Inc:

  • The MRQ is -300.827. Very Bad. -2
  • The TTM is -269.500. Very Bad. -2
Trends
Current periodCompared to+/- 
MRQ-300.827TTM-269.500-31.327
TTM-269.500YOY63.617-333.117
TTM-269.5005Y-158.461-111.039
5Y-158.46110Y-158.4610.000
Compared to industry (Drug Manufacturers-General)
PeriodCompanyIndustry (mean)+/- 
MRQ-300.827-0.722-300.105
TTM-269.500-0.006-269.494
YOY63.617-+63.617
5Y-158.461-0.292-158.169
10Y-158.461-0.062-158.399

2. Book Value per Share
2.3. Price to Book Ratio

Measures if the stock price of Merck is to cheap or to expensive compared to its book value.

  • At or below 1 is considered healthy (always compare to Drug Manufacturers-General industry mean).
  • A PB ratio of 4.83 means the investor is paying $4.83 for each $1 in book value.

Let's take a look of the Price to Book Ratio trends of Merck & Company Inc:

  • The EOD is 6.304. Seems overpriced? -1
  • The MRQ is 4.833. Neutral. Compare to industry.
  • The TTM is 2.467. Good. +1
Trends
Current periodCompared to+/- 
EOD6.304MRQ4.833+1.471
MRQ4.833TTM2.467+2.366
TTM2.467YOY1.340+1.127
TTM2.4675Y1.692+0.775
5Y1.69210Y1.6920.000
Compared to industry (Drug Manufacturers-General)
PeriodCompanyIndustry (mean)+/- 
EOD6.3042.964+3.340
MRQ4.8333.222+1.611
TTM2.4673.620-1.153
YOY1.3403.578-2.238
5Y1.6923.172-1.480
10Y1.6923.020-1.328
2. Total Gains per Share

3. Summary

3.1. Key Performance Indicators

The key performance indicators of Merck & Company Inc compared to the Most Recent Quarter (MRQ).

 End of day+/-Most Recent QuarterTrailing 12 Months+/-Year-Over-Year+/-5 Year+/-10 Year+/-
Book Value Change Per Share---0.736-100%0.651-100%1.900-100%1.900-100%
Book Value Growth---0.046-100%0.042-100%0.044-100%0.044-100%
Book Value Per Share--17.10016.367+4%12.010+42%13.895+23%13.895+23%
Book Value Per Share Growth---0.046-100%0.042-100%0.044-100%0.044-100%
Current Ratio--1.4591.378+6%1.164+25%1.274+15%1.274+15%
Debt To Asset Ratio--0.5960.611-3%0.668-11%0.644-7%0.644-7%
Debt To Equity Ratio--1.4751.581-7%2.078-29%1.857-21%1.857-21%
Dividend Per Share--0.6900.681+1%0.642+7%0.656+5%0.656+5%
Dividend Per Share Growth---0.0130.015-189%0.015-189%0.015-189%0.015-189%
Eps--1.2821.506-15%0.710+81%1.114+15%1.114+15%
Eps Growth---0.214-0.215+0%0.662-132%0.077-377%0.077-377%
Gross Profit Margin--1.0001.0000%1.0000%1.0000%1.0000%
Net Profit Margin--0.2170.259-16%0.145+50%0.205+6%0.205+6%
Operating Margin--0.3440.349-1%0.310+11%0.293+17%0.293+17%
Operating Ratio--0.9890.981+1%1.160-15%1.065-7%1.065-7%
Pb Ratio6.304+23%4.8332.467+96%1.340+261%1.692+186%1.692+186%
Pe Ratio84.079+23%64.46328.934+123%10.524+513%17.537+268%17.537+268%
Peg Ratio---300.827-269.500-10%63.617-573%-158.461-47%-158.461-47%
Price Per Share107.800+23%82.65039.678+108%18.973+336%26.067+217%26.067+217%
Price To Total Gains Ratio156.318+23%119.84983.789+43%46.685+157%71.421+68%71.421+68%
Profit Growth---21.429-9.857-54%-28.542+33%-19.200-10%-19.200-10%
Quick Ratio--0.4650.482-4%0.365+27%0.422+10%0.422+10%
Return On Assets--0.0300.036-15%0.020+56%0.028+8%0.028+8%
Return On Equity--0.0750.093-19%0.052+44%0.076-1%0.076-1%
Revenue Growth--0.0240.028-12%0.009+181%0.018+34%0.018+34%
Total Gains Per Share--0.6901.417-51%1.292-47%2.556-73%2.556-73%
Total Gains Per Share Growth---1.367-0.343-75%-3.227+136%-1.785+31%-1.785+31%
Usd Book Value--43318000000.00041461500000.000+4%30423500000.000+42%35201111111.111+23%35201111111.111+23%
Usd Book Value Change Per Share---0.736-100%0.651-100%1.900-100%1.900-100%
Usd Book Value Per Share--17.10016.367+4%12.010+42%13.895+23%13.895+23%
Usd Dividend Per Share--0.6900.681+1%0.642+7%0.656+5%0.656+5%
Usd Eps--1.2821.506-15%0.710+81%1.114+15%1.114+15%
Usd Price Per Share107.800+23%82.65039.678+108%18.973+336%26.067+217%26.067+217%
Usd Profit--3248000000.0003815000000.000-15%1799250000.000+81%2822000000.000+15%2822000000.000+15%
Usd Revenue--14959000000.00014743500000.000+1%12287750000.000+22%13408444444.444+12%13408444444.444+12%
Usd Total Gains Per Share--0.6901.417-51%1.292-47%2.556-73%2.556-73%
 EOD+2 -3MRQTTM+13 -22YOY+24 -115Y+22 -1310Y+22 -13

3.2. Fundamental Score

Let's check the fundamental score of Merck & Company Inc based on Penke's default stock scanner.

Penke's Stock Scanner

  
  
IndicatorConditionValue
Price to Earnings Ratio (EOD)Between0-1584.079
Price to Book Ratio (EOD)Between0-16.304
Net Profit Margin (MRQ)Greater than00.217
Operating Margin (MRQ)Greater than00.344
Quick Ratio (MRQ)Greater than10.465
Current Ratio (MRQ)Greater than11.459
Debt to Asset Ratio (MRQ)Less than10.596
Debt to Equity Ratio (MRQ)Less than11.475
Return on Equity (MRQ)Greater than0.150.075
Return on Assets (MRQ)Greater than0.050.030
Total4/10 (40.0%)

3.3. Technical Score

Let's check the technical score of Merck & Company Inc based on Penke's default Symbol scanner.

Penke's Symbol Scanner

  
  
IndicatorConditionValue
OpenGreater thanClose107.800
Total0/1 (0.0%)



Latest Balance Sheet

Balance Sheet of 2022-09-30. Currency in USD. All numbers in thousands.

Summary
 As reported
Total Liabilities -
Total Stockholder Equity+ -
Total Assets = -

Assets

Total Assets-
Total Current Assets33,561,000
Long-term Assets33,561,000
Total Current Assets
Net Receivables 10,685,000
Inventory 5,614,000
Other Current Assets 6,014,000
Total Current Assets  (as reported)33,561,000
Total Current Assets  (calculated)22,313,000
+/- 11,248,000
Long-term Assets
Property Plant Equipment 20,424,000
Long-term Assets  (as reported)0
Long-term Assets  (calculated)20,424,000
+/- 20,424,000

Liabilities & Shareholders' Equity

Total Current Liabilities22,998,000
Long-term Liabilities-
Total Stockholder Equity-
Total Current Liabilities
Accounts payable 3,973,000
Other Current Liabilities 4,503,000
Total Current Liabilities  (as reported)22,998,000
Total Current Liabilities  (calculated)8,476,000
+/- 14,522,000
Long-term Liabilities
Long-term Liabilities  (as reported)0
Long-term Liabilities  (calculated)0
+/-0
Total Stockholder Equity
Common Stock1,788,000
Other Stockholders Equity -4,743,000
Total Stockholder Equity (as reported)0
Total Stockholder Equity (calculated)-2,955,000
+/- 2,955,000
Other
Net Tangible Assets 1,930,000



Balance Sheet

Currency in USD. All numbers in thousands.

 Trend2022-09-302022-06-302022-03-312021-12-312021-09-302021-06-302021-03-312020-12-312020-09-30
> Total Assets 
89,800,000
91,588,000
90,847,000
90,688,000
93,494,000
105,694,000
106,668,000
107,095,000
0
0107,095,000106,668,000105,694,00093,494,00090,688,00090,847,00091,588,00089,800,000
   > Total Current Assets 
26,577,000
27,764,000
26,909,000
28,665,000
31,058,000
30,266,000
31,184,000
32,116,000
33,561,000
33,561,00032,116,00031,184,00030,266,00031,058,00028,665,00026,909,00027,764,00026,577,000
       Cash And Cash Equivalents 
7,356,000
8,062,000
6,981,000
8,575,000
10,016,000
8,096,000
8,556,000
9,675,000
0
09,675,0008,556,0008,096,00010,016,0008,575,0006,981,0008,062,0007,356,000
       Short-term Investments 
0
0
0
0
0
0
372,000
453,000
0
0453,000372,000000000
       Net Receivables 
8,422,000
8,288,000
8,692,000
8,378,000
10,581,000
10,779,000
11,192,000
10,983,000
10,685,000
10,685,00010,983,00011,192,00010,779,00010,581,0008,378,0008,692,0008,288,0008,422,000
       Inventory 
8,209,000
6,310,000
6,402,000
5,499,000
5,603,000
5,953,000
5,774,000
5,535,000
5,614,000
5,614,0005,535,0005,774,0005,953,0005,603,0005,499,0006,402,0006,310,0008,209,000
       Other Current Assets 
2,590,000
5,103,000
4,818,000
6,201,000
4,832,000
5,424,000
5,286,000
5,469,000
6,014,000
6,014,0005,469,0005,286,0005,424,0004,832,0006,201,0004,818,0005,103,0002,590,000
   > Long-term Assets 
63,223,000
63,824,000
63,938,000
62,023,000
62,436,000
75,428,000
75,484,000
74,979,000
0
074,979,00075,484,00075,428,00062,436,00062,023,00063,938,00063,824,00063,223,000
       Property Plant Equipment 
0
19,711,000
18,295,000
18,064,000
18,565,000
20,865,000
19,747,000
20,059,000
20,424,000
20,424,00020,059,00019,747,00020,865,00018,565,00018,064,00018,295,00019,711,0000
       Goodwill 
20,248,000
20,238,000
20,212,000
18,873,000
18,862,000
21,264,000
21,258,000
21,213,000
0
021,213,00021,258,00021,264,00018,862,00018,873,00020,212,00020,238,00020,248,000
       Long Term Investments 
1,372,000
785,000
544,000
411,000
435,000
370,000
316,000
238,000
0
0238,000316,000370,000435,000411,000544,000785,0001,372,000
       Intangible Assets 
16,677,000
14,604,000
14,401,000
13,622,000
13,384,000
22,933,000
23,022,000
22,497,000
0
022,497,00023,022,00022,933,00013,384,00013,622,00014,401,00014,604,00016,677,000
       Long-term Assets Other 
8,007,000
10,211,000
10,486,000
11,053,000
11,190,000
11,582,000
11,141,000
10,972,000
0
010,972,00011,141,00011,582,00011,190,00011,053,00010,486,00010,211,0008,007,000
> Total Liabilities 
60,530,000
66,184,000
63,808,000
57,300,000
57,631,000
67,437,000
65,715,000
63,777,000
0
063,777,00065,715,00067,437,00057,631,00057,300,00063,808,00066,184,00060,530,000
   > Total Current Liabilities 
20,405,000
27,327,000
26,361,000
21,906,000
23,728,000
23,872,000
22,316,000
23,168,000
22,998,000
22,998,00023,168,00022,316,00023,872,00023,728,00021,906,00026,361,00027,327,00020,405,000
       Short Long Term Debt 
2,420,000
6,431,000
7,251,000
2,488,000
3,534,000
2,412,000
1,208,000
2,979,000
0
02,979,0001,208,0002,412,0003,534,0002,488,0007,251,0006,431,0002,420,000
       Accounts payable 
3,744,000
4,594,000
4,034,000
3,897,000
4,248,000
6,389,000
6,026,000
4,621,000
3,973,000
3,973,0004,621,0006,026,0006,389,0004,248,0003,897,0004,034,0004,594,0003,744,000
       Other Current Liabilities 
0
4,567,000
4,181,000
3,838,000
4,341,000
3,276,000
3,802,000
3,866,000
4,503,000
4,503,0003,866,0003,802,0003,276,0004,341,0003,838,0004,181,0004,567,0000
   > Long-term Liabilities 
40,125,000
38,857,000
37,447,000
35,394,000
33,903,000
43,565,000
43,399,000
40,609,000
0
040,609,00043,399,00043,565,00033,903,00035,394,00037,447,00038,857,00040,125,000
       Long term Debt 
26,321,000
25,360,000
24,002,000
24,033,000
22,907,000
30,690,000
30,586,000
28,684,000
0
028,684,00030,586,00030,690,00022,907,00024,033,00024,002,00025,360,00026,321,000
       Other Liabilities 
0
12,135,000
13,445,000
11,361,000
10,996,000
11,650,000
12,813,000
11,925,000
11,077,000
11,077,00011,925,00012,813,00011,650,00010,996,00011,361,00013,445,00012,135,0000
       Long-term Liabilities Other 
12,027,000
12,482,000
12,241,000
9,872,000
9,469,000
9,434,000
9,742,000
8,951,000
0
08,951,0009,742,0009,434,0009,469,0009,872,00012,241,00012,482,00012,027,000
> Total Stockholder Equity
29,186,000
25,317,000
26,945,000
33,294,000
35,794,000
38,184,000
40,883,000
43,243,000
0
043,243,00040,883,00038,184,00035,794,00033,294,00026,945,00025,317,00029,186,000
   Common Stock
0
1,788,000
1,788,000
1,788,000
1,788,000
1,788,000
1,788,000
1,788,000
1,788,000
1,788,0001,788,0001,788,0001,788,0001,788,0001,788,0001,788,0001,788,0000
   Retained Earnings 
51,107,000
47,362,000
48,888,000
48,777,000
51,691,000
53,696,000
56,252,000
58,437,000
59,928,000
59,928,00058,437,00056,252,00053,696,00051,691,00048,777,00048,888,00047,362,00051,107,000
   Capital Surplus 000000000
   Treasury Stock000000000
   Other Stockholders Equity -4,743,000-4,327,000-4,369,000-4,429,000-4,590,000-4,628,000-6,622,000-6,634,0000



Balance Sheet

Currency in USD. All numbers in thousands.




Cash Flow

Currency in USD. All numbers in thousands.




Income Statement

Currency in USD. All numbers in thousands.


Latest Income Statement (annual, 2021-12-31)

Gross Profit (+$)
totalRevenue48,704,000
Cost of Revenue-13,626,000
Gross Profit35,078,00035,078,000
 
Operating Income (+$)
Gross Profit35,078,000
Operating Expense-35,505,000
Operating Income13,199,000-427,000
 
Operating Expense (+$)
Research Development12,245,000
Selling General Administrative9,634,000
Selling And Marketing Expenses-
Operating Expense35,505,00021,879,000
 
Net Interest Income (+$)
Interest Income36,000
Interest Expense-806,000
Net Interest Income-770,000-770,000
 
Pretax Income (+$)
Operating Income13,199,000
Net Interest Income-770,000
Other Non-Operating Income Expenses-
Income Before Tax (EBT)13,879,00012,519,000
EBIT - interestExpense = 15,051,000
14,570,000
13,855,000
Interest Expense806,000
Earnings Before Interest and Taxes (ebit)15,857,00014,685,000
Earnings Before Interest and Taxes (ebitda)13,199,000
 
After tax Income (+$)
Income Before Tax13,879,000
Tax Provision-1,521,000
Net Income From Continuing Ops12,358,00012,358,000
Net Income13,049,000
Net Income Applicable To Common Shares13,049,000
 
Non-recurring Events
Discontinued Operations704,000
Extraordinary Items-
Effect of Accounting Charges-
Other Items-
Non Recurring-
Other Operating Expenses-
Total Other Income/Expenses Net680,000770,000
 

Comments

Join the conversation.

Leave a comment

Stay informed with my latest content.

Subscribe to my newsletter and receive an email as soon as I add content to PenkeTrading.com.


By clicking Register, you agree to the General Terms and Conditions.
Penke's Market Notifications
AGM.LSE
7 minutes ago

I found you a RSI Bullish Reversal Divergence on the daily chart of AGM.LSE.

AGM.LSE Daily Candlestick Chart
AET.LSE
10 minutes ago

I found you a STOCH Bullish Hidden Divergence on the daily chart of AET.LSE.

AET.LSE Daily Candlestick Chart
AEX.INDX
10 minutes ago

I found you a Overbought RSI (Relative Strength Index) on the daily chart of AEX.INDX.

AEX.INDX Daily Candlestick Chart
ACKB.BR
14 minutes ago

I found you a Overbought RSI (Relative Strength Index) on the daily chart of ACKB.BR.

ACKB.BR Daily Candlestick Chart
3SIL.LSE
32 minutes ago

I found you a MACD Bearish Reversal Divergence on the daily chart of 3SIL.LSE.

3SIL.LSE Daily Candlestick Chart
0R40.LSE
1 hour ago

I found you a Death Cross on the daily chart of 0R40.LSE.

0R40.LSE Daily Candlestick Chart
0QGU.LSE
1 hour ago

I found you a Overbought RSI (Relative Strength Index) on the daily chart of 0QGU.LSE.

0QGU.LSE Daily Candlestick Chart
0QHL.LSE
1 hour ago

I found you a Overbought RSI (Relative Strength Index) on the daily chart of 0QHL.LSE.

0QHL.LSE Daily Candlestick Chart
0QGU.IL
1 hour ago

I found you a Overbought RSI (Relative Strength Index) on the daily chart of 0QGU.IL.

0QGU.IL Daily Candlestick Chart
0Q7S.LSE
1 hour ago

I found you a Overbought RSI (Relative Strength Index) on the daily chart of 0Q7S.LSE.

0Q7S.LSE Daily Candlestick Chart
0O8F.LSE
1 hour ago

I found you a Overbought RSI (Relative Strength Index) on the daily chart of 0O8F.LSE.

0O8F.LSE Daily Candlestick Chart
0NX0.LSE
1 hour ago

I found you a Overbought RSI (Relative Strength Index) on the daily chart of 0NX0.LSE.

0NX0.LSE Daily Candlestick Chart
0MPM.LSE
1 hour ago

I found you a STOCH Bullish Hidden Divergence on the daily chart of 0MPM.LSE.

0MPM.LSE Daily Candlestick Chart
0MPJ.LSE
1 hour ago

I found you a Golden Cross on the daily chart of 0MPJ.LSE.

0MPJ.LSE Daily Candlestick Chart
0MLH.IL
1 hour ago

I found you a Overbought RSI (Relative Strength Index) on the daily chart of 0MLH.IL.

0MLH.IL Daily Candlestick Chart
0J6X.LSE
1 hour ago

I found you a STOCH Bullish Reversal Divergence on the daily chart of 0J6X.LSE.

0J6X.LSE Daily Candlestick Chart
0IXZ.LSE
1 hour ago

I found you a Overbought RSI (Relative Strength Index) on the daily chart of 0IXZ.LSE.

0IXZ.LSE Daily Candlestick Chart
0IT3.IL
1 hour ago

I found you a Overbought RSI (Relative Strength Index) on the daily chart of 0IT3.IL.

0IT3.IL Daily Candlestick Chart
0HAH.LSE
1 hour ago

I found you a Overbought RSI (Relative Strength Index) on the daily chart of 0HAH.LSE.

0HAH.LSE Daily Candlestick Chart
0H3T.LSE
1 hour ago

I found you a Overbought RSI (Relative Strength Index) on the daily chart of 0H3T.LSE.

0H3T.LSE Daily Candlestick Chart
0EEE.LSE
1 hour ago

I found you a Overbought RSI (Relative Strength Index) on the daily chart of 0EEE.LSE.

0EEE.LSE Daily Candlestick Chart
0FM1.LSE
2 hours ago

I found you a Overbought RSI (Relative Strength Index) on the daily chart of 0FM1.LSE.

0FM1.LSE Daily Candlestick Chart
0DJI.LSE
2 hours ago

I found you a Overbought RSI (Relative Strength Index) on the daily chart of 0DJI.LSE.

0DJI.LSE Daily Candlestick Chart
JSCP.NYSE ARC
2 hours ago

I found you a Overbought RSI (Relative Strength Index) on the daily chart of JSCP.NYSE ARC.

JSCP.NYSE ARC Daily Candlestick Chart
JPMB.NYSE ARC
2 hours ago

I found you a Overbought RSI (Relative Strength Index) on the daily chart of JPMB.NYSE ARC.

JPMB.NYSE ARC Daily Candlestick Chart